AyuVis publishes the paper "Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis" in Nature Scientific Reports
In late Feburary of this year, AyuVis published the paper "Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis" in Nature Scientific Reports, which is a peer reviewed journal with online access. It is part of the Nature Research group and has a robust peer-review process.
Publishing this article was a strategic business and scientific goal. It puts AyuVis on the map and helps validate what we are doing. We are really pleased to have published a detailed full science paper on our first compound, AVR25, explaining the mechanism of action of this novel class of compounds and the exciting original sepsis efficacy data, around which the company was first formed. The authors are the major labs who have partnered with us at Drexel University, University of Cincinnati, Brown, Wash University in St Louis, and the University North Texas Health Science Center's Preclinical Service Center, where the company has lab space.
AyuVis Research to Present at the Biotech Showcase™ Annual Conference on January 7, 2019
Fort Worth, Texas - AyuVis Research Inc., a company developing small molecule immune-modulating agents that enhance the body’s ability to fight inflammation and restore lung function, is scheduled to present at Biotech Showcase™ 2019 taking place January 7-9, 2018 at the Hilton San Francisco Union Square, San Francisco, CA.
The company was founded in 2014 by Suchismita (Suchi) Acharya, PhD, a medicinal pharmaceutical scientist and entrepreneur, and works with scientific experts in neonatology, pediatrics, pulmonology, inflammation and microbiology to advance its pharmaceutical programs to treat severe inflammatory diseases.
Details for the presentation:
Date: January 7, 2019
Time: 9:00 am PST
Room: Hilton/Franciscan C, Ballroom Level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
AyuVis Research, Inc. is a pre-clinical stage pharmaceutical company focused on the discovery and development of novel, multi-functional small molecules that boost the body’s natural ability to fight disorders associated with inflammation, immune modulation and microbial infection. Its lead candidate is in pre-clinical-IND enabling studies for the treatment of Bronchopulmonary dysplasia, a pediatric orphan indication of severe lung injury. It also has pre-clinical assets for Pseudomonas aeruginosa lung and skin infection and systemic inflammatory response syndrome.
For more information, visit www.ayuvis.com.
AyuVis selected for the RESI Innovation Challenge in Boston, MA
Redefining Early Stage Investments (RESI) Conference
September 6th, 2018
The Fall Redefining Early Stage Investments (RESI) Conference was held September 6th, 2018 at the Boston Marriott Copley Place, Boston, MA
AyuVis was one of the thirty companies selected for the Innovation Challenge to showcase the company and products in the exhibit hall and gain more visibility from the early stage investors in attendance. These companies were selected from all the global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health that were attending the RESI Conference.
AyuVis published a poster titled:
Drug Development for Bronchopulmonary Dysplasia an Orphan Pediatric Disease
Author: Dr. Suchi Acharya in collaboration with Dr. Vineet Bhandari, Dr. Kurt Albertine, and Dr. Beamon Agarwal
The poster was presented by Dr. Acharya and Dr. Agarwal and generated excellent discussions about the lead and back-up compounds that have been developed, and the promising results from the pre-clinical tests. Treating preterm mice pups with the compounds showed marked improvement in lung development without affecting other organs. Treating BPD is a priority of the NIH due to the high cost of treatment and the current unmet need. The current treatment options have potential long term complications and costs for continued treatment.
AyuVis was invited to present a poster at the ACLPS Annual Meeting in Houston, Texas
53rd Annual ACLPS Meeting
May 31st to June 2nd, 2018
ACLPS 2018, the 53rd annual meeting of the Academy of Clinical Laboratory Physicians and Scientists (ACLPS), was held May 31 – June 2, 2018, at the Houston Methodist Hospital and Research Institute, Houston, Texas.
AyuVis was invited to present our scientific work on intra-abdominal infection and sepsis (cIAI) at the ACLPS Annual meeting. The poster title was:
Novel Chitohexaose Compounds to Treat Abdominal Peritonitis Leading to Sepsis
Authors: Dr. Beamon Agarwal, Dr. Pragnya Das, Dr. Santosh Panda, and Dr. Suchismita Acharya
The poster was presented by Dr. Beamon Agarwal and Dr. Suchi Acharya. The presentation attracted a large crowd that was keen to learn more about the progress we had made in developing a lead and several backup compounds, and favorable results achieved during the pre-clinical testing. This generated quite a bit of further discussion about the findings and results. The unique three pronged approach of immunomodulation, anti-inflammatory, and anti-microbial action positions the AyuVis compounds as a new class of drugs to treat cIAI.
For additional information, please contact Dr. Suchi Acharya at or Dr. Beamon Agarwal at
I-Corps at NIH
The I-Corps™ program is designed to support training that will help project teams at NIH- and CDC-funded small businesses overcome key obstacles along the path of innovation and commercialization.
5th Annual Congress on Bacteriology and Infectious Disease conference
Dr. Suchi Acharya, CEO, AyuVis Research did an invited oral presentation on the preclinical results of the small molecule technology for treating complicated intra-abdominal infection that leads to sepsis at the 5th Annual Congress on Bacteriology and Infectious Disease conference in Chicago during May 2017.
NIH SBIR funding for I-Corps
AyuVis Research has been selected as one of the 17 participants in I-Corps at NIH program. the I-Corps at NIH curriculum is designed to provide scientists from NIH SBIR funded companies with real-world, hands-on entrepreneurship training, facilitated by domain experts from the biotech sector. This program seeks to accelerate the development and commercialization of new products and services.AyuVis is expecting to gain immense experience to develop it's commercialization strategy for its proprietary small molecule technology for treating sepsis, and difficult to treat septic wounds. The program outcome along with Phase-I SBIR data will enable the team for a successful Phase-II SBIR from NIH/DOD and attract investors for angel/crowd funding.
Phase-I Small Business Innovative Research (SBIR) grant
AyuVis Research has been awarded a Phase-I Small Business Innovative Research (SBIR) grant funding from National Institute of Allergy and Infectious Diseases (NIAID) in January 2017 to conduct the preclinical proof of concept study of company’s proprietary multi functional small molecule for sepsis, septicemia.